Abstract
The use of DNA fragmentation assays for infertility patients remains controversial. Guidelines published by ASRM/AUA in October 2020 recommend offering testing in the setting of recurrent pregnancy loss. They also note that some causes of DNA fragmentation are easily reversible, and testicular sperm may be utilized in select cases. The objective of this study is to better understand current national practice patterns for use of DNA fragmentation testing, treatment options, and patient costs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
